

Figure S1. Survival curves of patients with cervical cancer according to PD-L1 expression. (A) OS, (B) LC and (C) PFS curves of patients who were PD-L1 positive (n=4) or negative (n=71) in pre-RT samples. (D) OS, (E) LC and (F) PFS curves of patients who were PD-L1 positive (n=39) or negative (n=36) post-10 Gy. (G) OS, (H) LC and (I) PFS curves of patients depending on PD-L1 alterations, with PD-L1 expression decreased (n=2), unchanged (n=35) or increased (n=38) after CRT/RT. PD-L1, programmed death-ligand 1; CRT, chemoradiotherapy; RT, radiotherapy; OS, overall survival; LC, locoregional control; PFS, progression-free survival.




Figure S2. Receiver operating characteristics curve for density of stromal CD8⁺ TILs to predict death or recurrence after RT. An analysis of the receiver operating characteristic curve was performed to determine the cut-off values for CD8⁺ TILs. TIL, tumor-infiltrating lymphocyte; RT, radiotherapy; AUC, area under the curve.




Figure S3. Survival curves of patients with cervical cancer according to PD-L1 expression and CD8⁺ TILs alterations after 10 Gy RT. (A) OS, (B) LC and (C) PFS curves of patients depending on stromal CD8⁺ TIL and PD-L1 alterations after 10 Gy RT. Results of statistical analyses are shown on the right. a, CD8⁺ TIL increased-PD-L1 increased; b, CD8⁺ TIL increased-PD-L1 unchanged/decreased; c, CD8⁺ TIL decreased-PD-L1 increased; and d, CD8⁺ TIL decreased-PD-L1 unchanged/decreased. OS, overall survival; LC, locoregional control; PFS, progression-free survival; PD-L1, programmed death-ligand 1; TIL, tumor-infiltrating lymphocyte; RT, radiotherapy.




Table SI. Days from the beginning of RT to post-10 Gy biopsies.

Days from the beginning of RT to biopsy	RT alone, n (%)	CRT, n (%)
5	0 (0.0)	1 (2.1)
7	1 (3.7)	1 (2.1)
8	18 (66.7)	35 (72.9)
9	6 (22.2)	11 (22.9)
11	2 (7.4)	0 (0.0)

CRT, chemoradiotherapy; RT, radiotherapy.

Table SII. Days from 10 Gy RT to biopsy of post-10 Gy samples.

Days from 10 Gy RT to biopsy	Patients, n (%)
0	4 (5.3)
1	56 (74.7)
2	4 (5.3)
3	9 (12.0)
4	2 (2.7)

RT, radiotherapy.